NDC Package 73362-101-01 Yorvipath

Palopegteriparatide Injection, Solution Subcutaneous - View Billable Units, 11-Digit Format, RxNorm

Package Information

Find all the important details about this NDC Package code, including the 11-Digit NDC Billing number, billing units, wholesale price, RxNorm crosswalk, active ingredients, pharmacologic clasess, etc.

NDC Package Code:
73362-101-01
Package Description:
2 BOX in 1 CARTON / 1 SYRINGE in 1 BOX (73362-101-02) / 1 CARTRIDGE in 1 SYRINGE (73362-101-03) / .98 mL in 1 CARTRIDGE
Product Code:
Proprietary Name:
Yorvipath
Non-Proprietary Name:
Palopegteriparatide
Substance Name:
Palopegteriparatide
Usage Information:
YORVIPATH is indicated for the treatment of hypoparathyroidism in adults.
11-Digit NDC Billing Format:
73362010101
Billing Unit:
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
NDC to RxNorm Crosswalk:
  • RxCUI: 2693637 - palopegteriparatide 168 MCG in 0.56 ML Pen Injector
  • RxCUI: 2693637 - 0.56 ML teriparatide 0.3 MG/ML Pen Injector
  • RxCUI: 2693637 - teriparatide 168 MCG (equivalent to palopegteriparatide 1935 MCG) per 0.56 ML Pen Injector
  • RxCUI: 2693643 - Yorvipath 168 MCG in 0.56 ML Pen Injector
  • RxCUI: 2693643 - 0.56 ML teriparatide 0.3 MG/ML Pen Injector [Yorvipath]
Product Type:
Human Prescription Drug
Labeler Name:
Ascendis Pharma, Endocrinology, Inc.
Dosage Form:
Injection, Solution - A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.
Administration Route(s):
Subcutaneous - Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL.
Sample Package:
No
FDA Application Number:
NDA216490
Marketing Category:
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date:
08-09-2024
Listing Expiration Date:
12-31-2025
Exclude Flag:
N
Code Structure:

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the disclaimer below.

Frequently Asked Questions

What is NDC 73362-101-01?

The NDC Packaged Code 73362-101-01 is assigned to a package of 2 box in 1 carton / 1 syringe in 1 box (73362-101-02) / 1 cartridge in 1 syringe (73362-101-03) / .98 ml in 1 cartridge of Yorvipath, a human prescription drug labeled by Ascendis Pharma, Endocrinology, Inc.. The product's dosage form is injection, solution and is administered via subcutaneous form.

Is NDC 73362-101 included in the NDC Directory?

Yes, Yorvipath with product code 73362-101 is active and included in the NDC Directory. The product was first marketed by Ascendis Pharma, Endocrinology, Inc. on August 09, 2024 and its listing in the NDC Directory is set to expire on December 31, 2025 if the product is not updated or renewed by the manufacturer.

What is the NDC billing unit for package 73362-101-01?

The contents of this package are billed per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.

What is the 11-digit format for NDC 73362-101-01?

The 11-digit format is 73362010101. The 11-digit billing format might be required by the Centers for Medicare & Medicaid Services (CMS) and other payers in billing claim forms.

This package code is originally configured in a 5-3-2 segment 10-digit format and by adding a zero within the original NDC package code we can obtain the converted 11-digit format in a 5-4-2 segment configuration. The table below shows the 11-digit code conversion:

10-Digit Format10-Digit Original Code11-Digit Format11-Digit Code
5-3-273362-101-015-4-273362-0101-01